logo

Fusion Pharmaceuticals Inc. (FUSN)



Trade FUSN now with
  Date
  Headline
11/8/2022 7:13:10 AM Fusion Pharmaceuticals Q3 Loss/shr Widens To $0.55 From $0.45 Last Year
8/29/2022 8:46:38 AM Fusion Says First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3
8/9/2022 7:22:06 AM Fusion Pharma Q2 Net Loss $19.1 Mln Or $0.44/Shr Vs Loss Of $26.9 Mln Or $0.63/Shr Last Year
6/23/2022 7:46:42 AM Fusion Pharma Announces FDA Clearance Of IND For FPI-2059
6/9/2022 7:06:42 AM Fusion Pharma Provides Updates On FPI-1434 And FPI-1966 Clinical Programs
5/10/2022 4:54:15 PM Wedbush Is Cutting Fusion Pharmaceuticals Inc. (FUSN) FY22 Estimate To -1.98 From -1.64
5/10/2022 4:54:01 PM Wedbush Is Lowering Fusion Pharmaceuticals Inc. (FUSN) Q4 22 Estimate To -0.43 From -0.39
5/10/2022 4:53:48 PM Wedbush Is Lowering Fusion Pharmaceuticals Inc. (FUSN) Q3 22 Estimate To -0.59 From -0.37
5/10/2022 4:53:32 PM Wedbush Is Cutting Fusion Pharmaceuticals Inc. (FUSN) Q2 22 Estimate To -0.53 From -0.48
5/10/2022 4:53:07 PM Wedbush Reiterates Fusion Pharmaceuticals Inc. (FUSN) At Outperform With $19 Down From $20 Price Target
5/10/2022 7:36:03 AM Fusion Pharma Q1 Net Loss Of $19.9 Mln Or $0.46/shr Vs Net Loss Of $17.5 Mln Or $0.42/shr Prior Year
3/24/2022 7:46:42 AM Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
3/17/2022 7:15:05 AM Fusion Pharma Q4 Net Loss $17.2 Mln Or $0.40/shr Vs Loss Of $13.4 Mln Or $0.32/Shr Last Year
3/17/2022 7:11:26 AM Fusion Pharmaceuticals Q4 Net Loss $17.2 Mln Vs. Net Loss $13.4 Mln Last Year
1/11/2022 8:20:30 AM Fusion Pharma Enters Research Collaboration With 48Hour Discovery To Develop Peptide-Based Radiopharmaceuticals
1/11/2022 8:19:36 AM Fusion Pharma Unveils Research Collaboration With Pepscan To Develop Peptide-Based Radiopharmaceuticals
11/9/2021 7:33:28 AM Fusion Pharma Q3 Net Loss $19.4 Mln Or $0.45/Shr Vs Loss Of $10.0 Mln Or $0.24/Shr Last Year